5 results on '"Llamas, Carlos Vallejo"'
Number of results to display per page
Search Results
2. Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
- Author
-
Chihara, Dai, primary, Gras, Luuk, additional, Zinger, Nienke, additional, Kröger, Nicolaus, additional, Mayer, Jiri, additional, Passweg, Jakob, additional, De Latour, Régis Peffault, additional, Byrne, Jenny, additional, Krüger, William, additional, Bohn, Jan-Paul, additional, Platzbecker, Uwe, additional, Blau, Igor Wolfgang, additional, Bonifazi, Francesca, additional, Helbig, Grzegorz, additional, McDonald, Andrew, additional, Mistrik, Martin, additional, Mohty, Mohamad, additional, Ram, Ron, additional, Sanz, Jaime, additional, Llamas, Carlos Vallejo, additional, Kreitman, Robert J., additional, Hayden, Patrick J., additional, McLornan, Donal, additional, Tournilhac, Olivier, additional, Van Gelder, Michel, additional, and Yakoub-Agha, Ibrahim, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Total body irradiation + fludarabine compared to busulfan + fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT
- Author
-
Giebel, Sebastian, Labopin, Myriam, Sobczyk-Kruszelnicka, Malgorzata, Stelljes, Matthias, Byrne, Jenny, Fegueux, Nathalie, Beelen, Dietrich, Rovira, Montserrat, Spyridonidis, Alexandros, Blaise, Didier, Bornhäuser, Martin, Karadogan, Ihsan, Savani, Bipin, Nagler, Arnon, Mohty, Mohamad, Martin, Sonja, Chevallier, Patrice, Neubauer, Andreas, Damaj, Gandhi, Koc, Yener, Ganser, Arnold, Collin, Matthew, Yakoub-Agha, Ibrahim, Ozdogu, Hakan, Araujo, Mercedes Colorado, Itäla-Remes, Maija, Orchard, Kim, Isaksson, Cecilia, Bethge, Wolfgang, Martin, Hans, Aljurf, Mahmoud, Faber, Edgar, Caballero, Dolores, Zák, Pavel, Leleu, Xavier, Bay, Jacques-Olivier, Rohrlich, Pierre-Simon, Kröger, Nicolaus, Huynh, Anne, Schäfer-Eckart, Kerstin, Milpied, Noel, Lenhoff, Stig, Ho, Aloysius, López, Jose Luis Bello, Mordini, Nicola, Lioure, Bruno, Halaburda, Kazimierz, Olivieri, Attilio, Gedde-Dahl, Tobias, Protheroe, Rachel, Tischer, Johanna, Klammer, Matthias, Clausen, Johannes, Potter, Victoria, Ladetto, Marco, Tilly, Herve, Deconinck, Eric, Brecht, Arne, Müller, Lutz Peter, Heinicke, Thomas, Carrete, Juan Pio Torres, Bazarbachi, Ali, Reményi, Péter, Rubio, Marie Thérèse, Fanin, Renato, Pérez-Simón, Jose Antonio, Niels, Murawski, Diez-Martin, J., Arat, Mutlu, Hermine, Olivier, Socié, Gerard, Cornelissen, Jan, Santarone, Stella, Guyotat, Denis, Bulabois, Claude Eric, Bernasconi, Paolo, Johansson, Jan-Erik, Vrhovac, Radovan, Greinix, Hildegard, Lorenzo, José Luis López, Apte, Shashikant, Craddock, Charles, Kobbe, Guido, Zahrani, Mohsen Al, Dreger, Peter, Lange, Andrzej, Tbakhi, Abdelghani, Meijer, Ellen, Llamas, Carlos Vallejo, Santasusana, Josep Maria Ribera, Corradini, Paolo, Benedetti, Fabio, Rambaldi, Alessandro, Gandemer, Virginie, Malfuson, Jean-Valère, Kaare, Ain, Risitano, Antonio, Petrini, Mario, Selleri, Carmine, Wu, Depei, Hematology, CCA - Cancer Treatment and quality of life, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
medicine.medical_specialty ,Transplantation Conditioning ,MESH: Busulfan ,Medizin ,MESH: Graft vs Host Disease ,Graft vs Host Disease ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Busulfan ,MESH: Hematopoietic Stem Cell Transplantation ,MESH: Transplantation Conditioning ,Retrospective Studies ,Transplantation ,Acute leukemia ,MESH: Humans ,MESH: Middle Aged ,business.industry ,Hazard ratio ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,MESH: Retrospective Studies ,Retrospective cohort study ,Hematology ,Middle Aged ,Total body irradiation ,Fludarabine ,Leukemia, Myeloid, Acute ,Regimen ,030220 oncology & carcinogenesis ,MESH: Vidarabine ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,MESH: Leukemia, Myeloid, Acute ,business ,MESH: Whole-Body Irradiation ,Vidarabine ,Whole-Body Irradiation ,030215 immunology ,medicine.drug - Abstract
International audience; The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-toxicity" regimens: intravenous busulfan at a total dose of 9.6 mg/kg (3 days) + fludarabine (Bu3/Flu) and total body irradiation at a dose of 8 Gy + fludarabine (TBI8Gy/Flu). In the entire study cohort (n = 518), the probabilities of overall survival (OS), leukemia-free survival (LFS), relapse and non-relapse mortality (NRM) at 2 years for Bu3/Flu and TBI8Gy/Flu were 62% vs. 72.5% (p = 0.051), 59.5% vs. 65% (p = 0.15), 30% vs. 20% (p = 0.01), and 10% vs. 14% (p = 0.18), respectively. In multivariate model for patients
- Published
- 2021
4. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
- Author
-
Bastidas, Adriana de la Serna, Javier El Idrissi, Mohamed and Oostvogels, Lidia Quittet, Philippe Lopez-Jimenez, Javier and Vural, Filiz Pohlreich, David Zuckerman, Tsila Issa, Nicolas C. Gaidano, Gianluca Lee, Je-Jung Abhyankar, Sunil and Solano, Carlos Perez de Oteyza, Jaime Satlin, Michael J. and Schwartz, Stefan Campins, Magda Rocci, Alberto Llamas, Carlos Vallejo Lee, Dong-Gun Tan, Sen Mui Johnston, Anna M. and Grigg, Andrew Boeckh, Michael J. Campora, Laura and Lopez-Fauqued, Marta Heineman, Thomas C. Stadtmauer, Edward A. and Sullivan, Keith M. Alonso Alonso, Aranzazu Anagnostopoulos, Achilles Andreadis, Charalambos (Babis) Angelopoulou, Maria and Anttila, Veli-Jukka Aoun, Mickael Barista, Ibrahim Berkahn, Leanne Bloor, Adrian J. C. Broady, Raewyn Brossart, Peter and Buadi, Francis K. Bulabois, Claude-Eric Cantin, Guy and Cellini, Claudia Chandrasekar, Pranatharthi Haran Chauncey, Thomas Cuneo, Antonio Dadwal, Sanjeet Singh Dickinson, Michael Eom, HyeonSeok Esquirol Sanfeliu, Albert Ferra Coll, Christelle Flomenberg, Phyllis R. Pilar Gonzalez-Rodriguez, Ana and Gottlieb, David J. Grisariu, Sigal Guenther, Andreas and Gutman, Jonathan Hahn, Uwe Heinz, Werner J. Heras, Inmaculada Ikeda, Takashi Jarque, Isidro Karthaus, Meinolf and Kerre, Tessa Kiani, Alexander Klein, Andreas K. Kofla, Grzegorz Kryuchkova, Irina V. Kuo, Ching-Yuan Kuruvilla, John Kuvshinov, Aleksey Kwak, Jae-Yong Lee, Jae Hoon and Lepretre, Stephane Lie, Albert Kwok-Wai Lucchesi, Alessandro and Maertens, Johan Marijt, Erik W. A. Martinez Munoz, Carmen and Michieli, Mariagrazia Milliken, Samuel T. Milpied, Noel and Monserrat Coll, Jorge Mossad, Sherif Beniameen Murphy, John and Navarro Matilla, Maria Belen Novak, Jan Olney, Harold J. Ona Navarrete, Raquel Pascual Cascon, Maria Jesus Peniket, Andy and Penka, Ganeva Piatkowska-Jakubas, Beata Polo Zarzuela, Marta and Quiel, Dimas Rowley, Scott D. Sabry, Waleed Salmi, Tommi Mikael Selleslag, Dominik L. D. Shea, Thomas C. Silling, Gerda Sinisalo, Ulla Marjatta Sohn, Sang Kyun Staib, Peter and Szer, Jeff Theunissen, Koen Topcuoglu, Pervin Tyurina, Natalya G. Uvarov, Mikhail Wahid, Fadilah S. Abdul Yanez San Segundo, Lucrecia Yegin, Zeynep Arzu Yeh, Su-Peng Yip, Sze-Fai Yoon, Sung Soo Young, Jo-Anne H. Zachee, Pierre and Zaja, Francesco ZOE-HSCT Study Grp Collaborators
- Abstract
IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases. RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P
- Published
- 2019
5. Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
- Author
-
Chihara D, Gras L, Zinger N, Kröger N, Mayer J, Passweg J, De Latour RP, Byrne J, Krüger W, Bohn JP, Platzbecker U, Blau IW, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas CV, Kreitman RJ, Hayden PJ, McLornan D, Tournilhac O, Van Gelder M, and Yakoub-Agha I
- Subjects
- Humans, Treatment Outcome, Transplantation, Homologous, Retrospective Studies, Leukemia, Hairy Cell therapy, Hematopoietic Stem Cell Transplantation
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.